Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Northstar Neuroscience Says It Has The Cash To Overcome EVEREST Setback

This article was originally published in The Gray Sheet

Executive Summary

Northstar Neuroscience says it has enough cash reserves to continue developing its cortical stimulation technology for tinnitus and depression, despite the disappointing results of the first pivotal trial for a stroke indication

You may also be interested in...



Research In Brief

Lung tumor ablation: Radiofrequency ablation, a common treatment for small liver tumors, is also a promising treatment strategy for patients with malignant lung tumors, researchers report in The Lancet Oncology (published by Elsevier, which also publishes "The Gray Sheet") June 18. A trial of 106 lung-tumor patients unsuitable for surgery, radiation or chemotherapy led by Riccardo Lencioni, University of Pisa, found that ablation is generally safe, with no procedure-related deaths. Of the 85 patients followed at least one year, 88% showed a complete response for the targeted tumors. A randomized trial is now warranted to compare ablation to standard treatment options, such as surgery, radiation and chemotherapy, the researchers say. AngioDynamics, which makes the 1500X RF/StarBurst ablation system used in the study and is seeking a lung tumor indication for the device, funded the research

Research In Brief

Lung tumor ablation: Radiofrequency ablation, a common treatment for small liver tumors, is also a promising treatment strategy for patients with malignant lung tumors, researchers report in The Lancet Oncology (published by Elsevier, which also publishes "The Gray Sheet") June 18. A trial of 106 lung-tumor patients unsuitable for surgery, radiation or chemotherapy led by Riccardo Lencioni, University of Pisa, found that ablation is generally safe, with no procedure-related deaths. Of the 85 patients followed at least one year, 88% showed a complete response for the targeted tumors. A randomized trial is now warranted to compare ablation to standard treatment options, such as surgery, radiation and chemotherapy, the researchers say. AngioDynamics, which makes the 1500X RF/StarBurst ablation system used in the study and is seeking a lung tumor indication for the device, funded the research

Neurotechnology Needs Better Outcome Measures, Diagnostics – VC Investors

The development and regulatory approval of new drugs and devices for treating diseases of the brain is hindered by the inadequacy of existing diagnostics and outcome measures, according to venture capitalists who spoke at a recent neurotech industry forum

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel